Found 171 matching trials
OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time
NAMonotherapy with a P2Y12 inhibitor after a minimum period of DAPT following...
Location
General Hospital of Northern Theater Command
Procedural Advantages of a Novel Drug-Eluting Coronary Stent
NAThis study sought to compare procedural performance of a new coronary stent...
Location
Multiple Locations
Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction
PHASE4The aim of the present trial is to assess the efficacy of the standalone us...
Location
Klinik fuer Innere Medizin III, Universitaetsklinikum des Saarlandes
INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial
PHASE3Randomized, blind controlled, Multicenter, spontaneous, prospective trial, ...
Location
Mediolanum Cardio Research
Clopidogrel Use and Long-term Safety After Drug-Eluting Stents Implantation
PHASE4The purpose of ZEST-LATE (Evaluation of the Long-term Safety After Zotaroli...
Location
Daegu Catholic University Medical Center
Drug Eluting Stent (DES) in Primary Angioplasty
PHASE2Stent implantation is the best treatment in patients with acute myocardial ...
Location
U.O. Cardiologia/UTIC
Cortisone or Drug Eluting Stents (DES) as Compared to Bare Metal Stents (BMS) to EliminAte Restenosis
PHASE2The possibility of using the new drug eluting stents (DES) technology has s...
Location
Istituto Clinico Humanitas
Single Long vs Two Short Overlapping Bioabsorbable Polymer DES
NAMultiple overlapping drug-eluting coronary stents (DES) are usually needed ...
Location
Ospedale Maggiore della Carità
A Comparison Between Paclitaxel-eluting Balloon in Combination With BMS Implantation vs Conventional Balloon and DES Implantation
PHASE4The purpose of this study is to evaluate the efficacy of predilation with p...
Location
Cardiovascular Department, Ospedale S.Donato
VQI DELTA Paclitaxel Device Safety Analysis
N/AThe VQI-DELTA Paclitaxel Device Safety Analysis seeks to assess the compara...
Location
Lahey Clinic, Inc.